TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21205592
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with drug eluting stents
Study: 18285440
Drug: Randomized treatments
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatments
Study: 10699160
Drug: Daclizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1.0 mg per kilogram of body weight), given intravenously within 24 hours after surgery and every two weeks thereafter for a total of five doses
Study: 10699160
Drug: Generalized immunosuppressive
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized immunosuppressive therapy (control group)
Study: 9124468
Drug: Melatonin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1 mg 30 min before and 0.75 mg 120 min after light exposure)
Study: 8166887
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg (n = 61)
Study: 25211359
Drug: Riboflavin solution
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin solution with 20% dextran
Study: 25211359
Drug: Dextran-free riboflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran-free riboflavin solution
Study: 22687313
Drug: Control (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotic therapy only)
Study: 16243989
Drug: ODT ondansetron
Normalized name: Ondansetron Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODT ondansetron 8 mg
Study: 10665675
Drug: Robot-aided therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-aided therapy during acute rehabilitation
Study: 10665675
Drug: Standard acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard acute rehabilitation treatment
Study: 2533023
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg/die for 14 days)
Study: 2533023
Drug: Piroxicam beta-cyclodextrin
Normalized name: piroxicam-beta-cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam beta-cyclodextrin (20 mg/die for 14 days)
Study: 24294744
Drug: Local probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local probiotics vaginal medicine (10 applications) containing Lactobacillus acidophilus and Lactobacillus rhamnosus
Study: 24294744
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day)
Study: 24294744
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day) + local probiotics (starting day 5)
Study: 21569374
Drug: Temporary ovarian
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary ovarian suspension (elevating both ovaries to the anterior abdominal wall using a Prolene suture) post-operatively
Study: 11134099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 100 mg/day
Study: 11134099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 50 mg to 75 mg/day
Study: 11134099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 100 mg to 75 mg/day
Study: 11134099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (both doses)
Study: 26928845
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel
Study: 11134099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch (2 patches delivering 5 mg T/day)
Study: 9307537
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prostaglandin E2 (2 mg)
Study: 8349432
Drug: Oral menogaril
Normalized name: ceftobiprole medocaril sodium Injection [Zevtera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral menogaril (85 mg/m2 to 625 mg/m2 every 4 weeks)
Study: 8349432
Drug: Alternating oral
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating oral and IV menogaril (250 mg/m2 IV; 250-500 mg/m2 oral)
Study: 8349432
Drug: Oral menogaril
Normalized name: ceftobiprole medocaril sodium Injection [Zevtera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral menogaril
Study: 19068454
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day, 4 weeks 'on' and 2 weeks 'off')
Study: 10937788
Drug: Computer-administered SCL-90-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered SCL-90-R
Study: 8146033
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg maprotiline
Study: 8146033
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aminophylline
Study: 2873974
Drug: Lidamidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidamidine (10 mg per os)
Study: 21332653
Drug: 100‐min infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100‐min infusion of gemcitabine
Study: 21332653
Drug: 30‐min infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐min infusion of gemcitabine
Study: 21332653
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion after week 1
Study: 15060511
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg orally once daily for 4 days
Study: 11755894
Drug: ADL 8‐2698
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADL 8‐2698 (6.0 mg)
Study: 11755894
Drug: ADL 8‐2698
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADL 8‐2698 (0.5 to 3.0 mg)
Study: 11755894
Drug: ADL 8‐2698
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADL 8‐2698 (> or = 3.0 mg)
Study: 11755894
Drug: ADL 8‐2698
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADL 8‐2698 (lower doses)
Study: 7867676
Drug: Valsartan 40
Normalized name: valsartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 40 mg
Study: 2840815
Drug: Lisinopril 2.5
Normalized name: lisinopril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 2.5 mg
Study: 3617239
Drug: Combined intramuscular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intramuscular and oral estrogen treatment (ESTR, n = 39)
Study: 22211444
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention to decrease HIV-related risk behavior and trauma-related stress symptoms
Study: 15987864
Drug: Multivitamin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplementation (20 mg thiamine, 20 mg riboflavin, 25 mg B-6, 50 microg B-12, 500 mg C, 30 mg E, and 0.8 mg folic acid)
Study: 15987864
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (30 mg beta-carotene plus 5000 IU preformed vitamin A)
Study: 10702649
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine
Study: 27899067
Drug: Conventionally estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally estimated drug effect
Study: 25298576
Drug: Conventional interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional interferon (INF) α2a, 3MIU, S.C and ribavirin 1000 mg PO for 24 weeks in genotype 3 and 48 weeks in genotype 1 and 4 HCV patients.
Study: 22670901
Drug: Delamanid 100
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid 100 mg twice daily
Study: 22670901
Drug: Delamanid 200
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid 200 mg twice daily
Study: 17885344
Drug: Heatwrap therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heatwrap therapy in addition to oral analgesics
Study: 26058405
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics (control group)
Study: 12183263
Drug: Gentamicin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin concentration at surgical closure < 0.5 mg/liter
Study: 12183263
Drug: Gentamicin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin concentration at surgical closure ≥ 1.6 mg/liter
Study: 10728175
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for bulimia nervosa
Study: 9815934
Drug: Cisplatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, 80 mg/m2, three times every 3 weeks
Study: 9815934
Drug: Carboplatin, 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin, 375 mg/m2, three times every 3 weeks
Study: 1952429
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (0.025 mg/kg body weight)
Study: 7281826
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PETN
Study: 7281826
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg PETN
Study: 30765429
Drug: Proximal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Study: 30765429
Drug: Distal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Study: 30765429
Drug: Intravenous isoglycemic
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isoglycemic clamp studies
Study: 28993935
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n=39)
Study: 28993935
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (n=18)
Study: 15941455
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment programme (n = 21)
Study: 6600426
Drug: Aspirin (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2.6 g/day)
Study: 30578873
Drug: Risankizumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (90 mg)
Study: 30578873
Drug: Risankizumab (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (180 mg)
Study: 19776683
Drug: High group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High group (target serum glucose concentration 9‐11 mmol/l)
Study: 19776683
Drug: Low group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low group (target serum glucose concentration 5‐7 mmol/l)
Study: 17276272
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with intracameral nonpreserved lidocaine 0.5% (Group 2)
Study: 17276272
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with 0.15 mL intracameral placebo (Group 1)
Study: 9825370
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg over 15 minutes followed by 10 mg/kg over the next 24 hours)
Study: 9825370
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg intravenously over 1 hour, followed by 20 mg/kg over the next 24 hours, plus 1,800 mg/day orally, in 3 divided doses)
Study: 7926530
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen inhalation (n = 30)
Study: 7926530
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous sedation (pethidine 50 mg, midazolam 2.5 mg) (n = 29)
Study: 25692479
Drug: TiZr implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiZr implants
Study: 24713048
Drug: Ti Grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ti Grade IV implants
Study: 24006085
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) in combination with chemotherapy
Study: 20868428
Drug: G3 -
Normalized name: IgG3 - Immunoglobulin G3
Approvals — FDA: no, EMA: no, PMDA: no
Description: G3 - Biosilicate® incorporated in a 1% water‐free‐gel (n=59)
Study: 19066100
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (within 7-24 hours)
Study: 19066100
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ultra-early stage < or = 7 h)
Study: 19066100
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (delayed stage > 24 h)
Study: 12593901
Drug: Coil removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coil removal prior to treatment
Study: 11131487
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (cisplatin-based)
Study: 8350219
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (4.4 mg/L; final content, 11 mg/L)
Study: 8350219
Drug: Placebo (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (final content, 6.7 mg/L)
Study: 27177859
Drug: Patients reporting
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients reporting primary goal of treatment as 'cure my cancer'
Study: 30724096
Drug: Elagolix 150
Normalized name: elagolix 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 150 mg
Study: 23885105
Drug: Elagolix 250
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix 250 mg
Study: 12090980
Drug: Intranasal 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 4% sodium cromoglicate spray
Study: 12090980
Drug: Intranasal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal normal saline spray
Study: 8619016
Drug: Melatonin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.5 mg) for 7 days
Study: 6119168
Drug: Oxatomide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (2 mg/kg by mouth)
Study: 6119168
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate powder (20 mg by inhalation)
Study: 6119168
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo preparations
Study: 31129603
Drug: Electronic cigarettes
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic cigarettes with nicotine (ECwN) plus placebo tablets of varenicline
Study: 31129603
Drug: Electronic cigarettes
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic cigarettes without nicotine (ECwoN) plus placebo tablets of varenicline
Study: 31129603
Drug: Electronic cigarettes
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic cigarettes without nicotine (ECwoN) plus 0.5 mg varenicline tablets
Study: 30235712
Drug: 5, 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5, 10, 15, 20, and 25 μg epidural sufentanil as an adjuvant with 10 mL of 0.65% ropivacaine
Study: 26921890
Drug: Medication-specific education
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-specific education (video and written information about the medication prescribed)
Study: 26921890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication-specific education)
Study: 26921890
Drug: Medication-specific education
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-specific education
Study: 17539693
Drug: Antipsychotic drug
Normalized name: antipsychotic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drug regimens that do not adversely affect major risk factors for CVD
Study: 12115219
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of methotrexate (MTX), hydroxychloroquine (HCQ), and sulfasalazine (SSZ)
Study: 10195337
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment with neuroleptics
Study: 8645833
Drug: Ceftriaxone (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1-g dose)
Study: 2138532
Drug: GR 38032F
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR 38032F (16 mg orally thrice daily)
Study: 6118250
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg b.i.d. orally for 3 days)
Study: 6118250
Drug: Ketotifen (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (7-day medication)
Study: 24476082
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) urinary hCG injection
Study: 24476082
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) recombinant hCG injection
Study: 24476082
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection (both i.m. and s.c.)
Study: 24476082
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection (s.c.)
Study: 18684076
Drug: Japanese acupuncture
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese acupuncture treatment
Study: 15999118
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride/day for 4 weeks prior to surgery
Study: 15999118
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no finasteride treatment)
Study: 14600543
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg.d(-1)) and beta-carotene (20 mg.d(-1)) in subjects with heavy exercise at leisure
Study: 1460451
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg oral dose
Study: 1460451
Drug: Terconazole 80
Normalized name: terconazole 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terconazole 80 mg vaginal suppository daily for 3 days
Study: 26823269
Drug: Structured intervention
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured intervention with written stepped-dose reduction (SIW)
Study: 26823269
Drug: Structured intervention
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured intervention with stepped-dose reduction and follow-up visits (SIF)
Study: 15923574
Drug: Elderly patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly patients receiving any cancer treatment
Study: 8929750
Drug: Potassium diclofenac
Normalized name: Diclofenac Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium diclofenac suspension (Flogan, Merck, 7ml, 105 mg) after food intake (FOOD phase)
Study: 8929750
Drug: Potassium diclofenac
Normalized name: Diclofenac Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium diclofenac suspension (Flogan, Merck, 7ml, 105 mg) after gastric acid secretion blockade (OME phase)
Study: 1754989
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of dexamethasone (11.00 p.m.)
Study: 1754989
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of dexamethasone (08.00 a.m.)
Study: 31760207
Drug: Real cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real cupping therapy (15 minutes, bilaterally at points BL23, BL24, BL25)
Study: 31760207
Drug: Placebo cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cupping therapy
Study: 26248442
Drug: Masking Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masking Therapy (Control)
Study: 15943568
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg hydroxyurea
Study: 15943568
Drug: 800-900 mg
Normalized name: guaifenesin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-900 mg hydroxyurea
Study: 10485504
Drug: omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 40 mg/d
Study: 10485504
Drug: lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 15 mg/d
Study: 10485504
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg/d
Study: 1929762
Drug: Clomipramine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine therapy (nonsubstituted group)
Study: 7037983
Drug: Live RSV
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live RSV vaccine
Study: 26613790
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg chromium supplements
Study: 10894101
Drug: Respocort (250-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respocort (250-1000 microg per dose; cumulative dose 2000 microg)